Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa - Wikidata - awgldk - TriplyDB

Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa

Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa

http://www.wikidata.org/entity/Q34228382

about

Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design Does High-Dose Antimicrobial Chemotherapy Prevent the Evolution of Resistance?Rapid conversion of Pseudomonas aeruginosa to a spherical cell morphotype facilitates tolerance to carbapenems and penicillins but increases susceptibility to antimicrobial peptides.Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance Hospital-acquired infections due to gram-negative bacteria.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.Acinetobacter baumannii: emergence of a successful pathogen Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors.Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.Short versus long infusion of meropenem in very-low-birth-weight neonates Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.Continuous beta-lactam infusion in critically ill patients: the clinical evidence Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae The importance and future of antimicrobial surveillance studies.Pharmacokinetic and pharmacodynamic properties of meropenem.Meropenem pharmacokinetics in the newborn.Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa.Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children.Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.In vitro pharmacodynamic models to determine the effect of antibacterial drugs.Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media.Treatment option for sepsis in children in the era of antibiotic resistance.Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria.Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.Optimization of therapy against Pseudomonas aeruginosa with ceftazidime and meropenem using chemostats as model for infections.Emergence of antimicrobial resistance to Pseudomonas aeruginosa in the intensive care unit: association with the duration of antibiotic exposure and mode of administration.Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study.Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.[Therapeutic drug monitoring and individual dosing of antibiotics during sepsis : Modern or just "trendy"?]

P2860

Q24675002-366B04AA-821F-4E34-8311-F908F2AB2BF2 Q28476705-888B4BB9-A297-443D-95B0-289D89BFE575 Q28552950-5B71DC53-41D0-4B2F-A581-B3488E98B6AF Q33622802-7491A4F3-5FF2-4D70-BB34-EA8BED7F223F Q33767602-89615092-8C7C-455A-8E7F-24DF43958144 Q33798203-E2DA22E8-A387-4E17-BD7C-79534BFED3C3 Q33876543-B1F7F4A7-34FF-4F2A-A6DB-7A57D3C668E9 Q34114983-F78673DD-E824-40FD-9697-5F318EE504A9 Q34274190-8BB87619-1135-47AE-8427-E4FB8300EE83 Q34596344-98B1545A-0DC7-4A67-864A-12158AEDEE93 Q34795807-550E9FA3-B5A3-4034-BE1B-9209809C859C Q35759054-C478443D-3049-432D-8173-C4561B1B570C Q35941209-C1D9F264-AA94-4CCA-903B-ACAFA7CCF95B Q35960828-7ED8FFCA-4F9B-40FD-8615-92B81070ACFC Q35986250-AFF3F857-249B-4F18-9671-107F4C5AE546 Q36095041-655BB765-093D-4317-AD69-CE528DB55BB2 Q36172523-5A878B0C-ABA9-4BEA-BAD1-565FC4BD31BD Q36287127-7324269E-C4DD-4050-82F9-A4B7980594B5 Q36329228-6BE56D94-CB51-48FE-B6AC-FCBFFD9209E0 Q36396195-5BDBF7F2-C586-49E8-882E-10CD46886571 Q36633761-F08A9ED3-9428-47CD-AB65-DD68F34F8AA9 Q37023175-7C202F5B-E935-4184-AC23-F4CE3879D3A8 Q37247114-947849DC-AF46-415A-84AF-911DD803F563 Q37247125-435F4369-E8C1-40AA-B925-A336C628054B Q37333159-7E16BBDB-F7D5-4991-A808-741701689568 Q37335725-DE809E6D-DF56-4344-971C-69A90075C1FE Q37335844-E5C29E34-97F8-4CB1-9AF0-157F0DB86C5B Q37538623-A7EA0BB3-2BF5-4B97-88AD-D5CB25F677D3 Q37660762-7C623AB5-AC22-4619-BC7E-1CE2E8CEFEC6 Q37669021-261F9B32-A007-4BC2-9BF6-357C312F6B9B Q38246118-F506C22F-0843-456A-B5C4-DC7DF8F90709 Q39293585-4B72E3CF-5DC3-4860-940E-E563809E11E4 Q39344408-3025D133-AE76-4B1E-84E3-A9906C6F20F4 Q39702978-DD0464A6-154A-4E31-BA0B-8D043FA18EEF Q40074463-F3D32AC9-3EB5-4A88-A243-CAD0E70E3E73 Q40152779-BB51C07F-7257-4C89-8BD4-5F5C86CCAFA1 Q40206253-F8AE1025-0ABC-4C1E-B732-BE8DBFC1FFFF Q40306198-BE9478BF-A83E-4E4F-BBB8-2516B1E6EE23 Q40346786-059E9BB8-660B-4162-B32E-4FF00D3AE43B Q40541397-C942442A-0AAC-4C72-9A8E-230ACE2621DD

P2860

Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa

http://www.wikidata.org/entity/Q34228382

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Optimization of meropenem mini ...... ance of Pseudomonas aeruginosa

@ast

Optimization of meropenem mini ...... ance of Pseudomonas aeruginosa

@en

Optimization of meropenem mini ...... ance of Pseudomonas aeruginosa

@nl

type

label

Optimization of meropenem mini ...... ance of Pseudomonas aeruginosa

@ast

Optimization of meropenem mini ...... ance of Pseudomonas aeruginosa

@en

Optimization of meropenem mini ...... ance of Pseudomonas aeruginosa

@nl

prefLabel

Optimization of meropenem mini ...... ance of Pseudomonas aeruginosa

@ast

Optimization of meropenem mini ...... ance of Pseudomonas aeruginosa

@en

Optimization of meropenem mini ...... ance of Pseudomonas aeruginosa

@nl

P1433

Q34228382-3066CB8A-2143-4596-A879-13A46A1C2A45

P1476

Q34228382-1959E783-DF57-4C15-8C4E-EA377DA84B51

P2093

Q34228382-17A88229-3B60-4D4D-A054-1FEB4EB185F8

Q34228382-32509435-405B-4382-8302-358A930CF404

Q34228382-68F1CDE9-1FC1-4E2F-9F4C-2630A1407015

Q34228382-729322D7-4FF1-4AD4-B9B7-CAE812070FDB

Q34228382-BD9D9F66-FD1E-4E1C-BE5E-3146E3A44F9A

Q34228382-F47650A5-5A39-4414-B188-7CB19CB3FC8F

P2860

Q34228382-007258BD-EE37-4B82-8F7E-352B31741CAF

Q34228382-0396937D-1FFE-487B-A0CF-EA9ECE6AC483

Q34228382-157B34D9-61FD-428D-B61D-21CED1CA1C9C

Q34228382-1925DF15-9CA4-44D9-8043-1B8DBCEC1C90

Q34228382-2D54B043-A4BE-4316-B1B5-45E0516970DD

Q34228382-2DA5B06E-48D9-4E58-B46C-A69B54405E4B

Q34228382-36B0AC1B-88FA-49B6-B712-2975696C4700

Q34228382-3E439F3C-DDF8-4C1A-B0CC-F5E25343B5A2

Q34228382-6DC3658C-B17D-46E1-84D9-B7A93027B813

Q34228382-777CE371-6F0C-4B2D-9902-1E0FEBB64811

P304

Q34228382-B2BA091B-6D00-4751-9C19-A198C21BB971

P31

Q34228382-B7FF8F53-6974-4AB1-B4C5-90E8CF79179C

P356

Q34228382-C296CA3B-1137-4119-9C4D-3CB208663F72

P407

Q34228382-9198BCA3-9CD0-4D99-B12D-EB78E7533169

P433

Q34228382-7F1F0545-18E0-4255-8614-C106F6167C66

P478

Q34228382-1EFC4C59-AE52-4AC5-8C37-6A029B0A263C

P577

Q34228382-D6082965-3CEC-4EB8-AC31-3AA2E79B85BD

P698

Q34228382-15985149-AB83-4BC8-A26B-12C3E06F5488

P921

Q34228382-7FD6D9CD-2766-4493-8D36-27CA3DC89B93

P932

Q34228382-C4DE9BFA-40AB-47DC-9C1D-4968C6A5CC45

P356

AAC.49.12.4920-4927.2005

P1433

Antimicrobial Agents and Chemotherapy

P1476

Optimization of meropenem mini ...... ance of Pseudomonas aeruginosa

@en

P2093

Amy N Schilling

http://www.w3.org/2001/XMLSchema#string

David A Melnick

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Coyle

http://www.w3.org/2001/XMLSchema#string

Keith Poole

http://www.w3.org/2001/XMLSchema#string

Shadi Neshat

http://www.w3.org/2001/XMLSchema#string

Vincent H Tam

http://www.w3.org/2001/XMLSchema#string

P2860

Influence of mutations in the mexR repressor gene on expression of the MexA-MexB-oprM multidrug efflux system of Pseudomonas aeruginosa

In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.

Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems.

Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations.

Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients

Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.

Pharmacodynamics of S-3578, a novel cephem, in murine lung and systemic infection models

Clinical pharmacodynamics of quinolones.

Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies.

P304

4920-4927

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.49.12.4920-4927.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16304153

http://www.w3.org/2001/XMLSchema#string

P921

Pseudomonas aeruginosa

P932

1315965

http://www.w3.org/2001/XMLSchema#string